Clinical trials: Any Cancer
Prostate Cancer
Bicalutamide Compared With Observation Followed by Bicalutamide Plus Either Goserelin or Orchiectomy in Treating Patients With Prostate Cancer
RATIONALE: Testosterone can stimulate the growth of cancer cells. Bicalutamide and goserelin may fight prostate cancer by reducing the production of testosterone.
- Trial name
- NCT00014586
- Testing
- bicalutamide, goserelin acetate, orchiectomy
- Where
- Germany
- Volunteers
- 110 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Glioma (Any Grade) in the Brain
Study on The Sensitizing Effect of Sonodynamic Therapy on The Treatment of Brainstem Glioma With Radiotherapy and Chemotherapy and Survival Analysis
1.Brief Introduction to the Research Background: You are invited to participate in a clinical study initiated by the First Affiliated Hospital of Zhengzhou University and chaired by Professor Zheng Yingjuan at our center.
- Trial name
- NCT06999148
- Testing
- Sonodynamictherapy, Radiotherapy plus temozolomide
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Yingjuan Zheng
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Uterine Cancer
Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
Objectives: To determine the maximum tolerated dose (MTD) of imatinib mesylate in combination with fixed dose paclitaxel in patients with stage IIIC, IV or recurrent uterine papillary serous carcinoma.
- Trial name
- NCT00506779
- Testing
- Imatinib Mesylate, Paclitaxel
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
NSCLC Stage IV, NSCLC Stage IIIB
Comparison of Genomic and Transcriptomic Patterns Between CTC and Metastatic Tumormetastatic Tumor
This study aims to understand the metastasis in advanced NSCLC through comparing genomic and transcriptomic patterns between the circulating tumor cells and metastatic tumor cells by single cell sequencing analysis.
- Trial name
- NCT04932343
- Testing
- cohort study
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Samsung Medical Center
Angiosarcoma
Prospective Observational Study of Localized Angiosarcoma of Any Site: ProStars
This study will be a multi-institutional, prospective, observational study of patients with localized primary AS of any site within ISG and RTR centers.
- Trial name
- ProStars (NCT06375941)
- Testing
- Observational
- Where
- 19 sites in Italy
- Volunteers
- 250 people
- Sponsor
- Italian Sarcoma Group
Cancer
GOLD: Brief Intervention to Reduce Anxiety and Promote Resilience in Families of Youth With Cancer
The purpose of this study is to examine a psychotherapeutic and psycho-educational intervention offered in virtual settings to caregivers of youth with cancer.
- Trial name
- NCT05415007
- Testing
- GOLD Program, Treatment as usual (TAU)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Stanford University
Acute Myeloid Leukemia (AML)
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults.
- Trial name
- NCT04813263
- Where
- 281 sites in Japan
- Volunteers
- 424 people
- Sponsor
- AbbVie
Lung Cancer
Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if surgery is more effective with or without preoperative chemotherapy in treating…
- Trial name
- NCT00003159
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 2 sites in United Kingdom
- Volunteers
- 600 people
- Sponsor
- Medical Research Council
Melanoma
Intraoperative Mapping of Regional Lymphatics Draining the Primary Site of Melanoma Using Isosulfan Blue
The purpose of this study is to determine whether we can consistently identify the first lymph node (the "sentinel node") draining your melanoma.
- Trial name
- NCT00581698
- Where
- United States
- Volunteers
- 876 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cancer
Efficacy Study on Quality of Life Criteria of a Digital Application on Any Cellphone (OnKO-Tips&Tricks) for Adolescents and Young Adults Diagnosed With Cancer
Approximately 2,200 cancers per year in France are diagnosed within the adolescents and young adults population (15-25 years old, AYA).
- Trial name
- OnKO T&T 2 0 (NCT05350631)
- Testing
- OnKO-Tips&Tricks digital phone application
- Where
- 10 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Advanced Gastric Adenocarcinoma
Phase Ib, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel, in Any Solid Cancer and Sequential Phase II, Single-arm Study of AZD6094 (Volitinib) in Combination With Docetaxel in Advanced Gastric Adenocarcinoma Patients With MET Amplification as a Second Line Treatment
Phase Ib/II, single-arm study of AZD6094 (Volitinib) in combination with docetaxel, in advanced gastric adenocarcinoma patients with MET amplification as a second-line treatment.
- Trial name
- NCT02447406
- Testing
- AZD6094, docetaxel
- Where
- South Korea
- Volunteers
- 7 people
- Sponsor
- Samsung Medical Center
NF type1 With Inoperable Plexiform Neurofibromas
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
This will be an open-label, single-arm, multicenter intermediate access protocol which provides treatment access to selumetinib for eligible patients with neurofibromatosis type 1 (NF1) who have inoperable…
- Trial name
- NCT03259633
- Testing
- Selumetinib
- Where
- United States
- Sponsor
- AstraZeneca
Lung Neoplasms, Gene, p53
Is There Any Relation Between Serum Anti-p53 Antibody and TLG, MTV and SUV as PET Parameters in Lung Cancer Patients?
p53 is a tumor suppressor gene which plays an important role in controlling normal cell proliferation regulation that is located on the chromosome 17 (17p13.1). It is the most common goal of genetic alteration in many tumors.
- Trial name
- NCT02309567
- Testing
- Blood Collection
- Where
- Turkey (Türkiye)
- Volunteers
- 146 people, healthy volunteers welcome
- Sponsor
- Cumhuriyet University
Metastatic Solid Tumors (Any Localization)
Molecular Screening for Cancer Treatment Optimization
The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival…
- Trial name
- MOSCATO 02 (NCT01566019)
- Testing
- Tumoral biopsy
- Where
- France
- Volunteers
- 2,150 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Glioma (Any Grade) in the Brain
18F-Floretyrosine Expanded Access Program
The aim of this Expanded Access Program (EAP) is to enable the use of 18F-Floretyrosine with positron emission tomography/computed tomography (PET/CT) or positron emission tomography/magnetic resonance (PET/MR) imaging to…
- Trial name
- NCT06743100
- Testing
- 18F-Floretyrosine
- Where
- 10 sites in United States
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Limited
Malignant Solid Neoplasm
Testing Copanlisib as Potentially Targeting Treatment in Cancers With PTEN Loss (MATCH - Subprotocol Z1G)
The phase II MATCH treatment trial tests how well copanlisib works to treat patients with cancer with PTEN loss. Copanlisib may stop the growth of tumor cells and may kill them by blocking some of the enzymes needed for cell…
- Trial name
- NCT06360588
- Testing
- Biopsy Procedure, Biospecimen Collection, Copanlisib
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma
Peripheral Blood and/or Bone Marrow, Including Detection of Occult Metastases, in Patients With Melanoma
The purpose of this study is to determine if tumor cells can be detected in the peripheral blood and/or bone marrow of patients with melanoma.
- Trial name
- NCT00588198
- Where
- United States
- Volunteers
- 754 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lynch Syndrome
Diagnosis of Lynch Syndrome Based on Next-generation Sequencing in Colorectal Cancer
The purpose of this study is to determine the proportion of patients diagnosed with Lynch syndrome in colorectal cancer patients with the loss of staining by immunohistochemistry (IHC) of any of the mismatch repair (MMR)…
- Trial name
- NCT03047226
- Testing
- next-generation sequencing
- Where
- 7 sites in China
- Volunteers
- 311 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Dermatitis, Adverse Drug Reaction
MARY DUOL REPAIR BALM IN THE PREVENTION OR REDUCING ANTINEOPLASIC AGENTS' SKIN TOXICITY
Capecitabine is a drug that produces dermatologic toxicity frequently (palmoplantar erythrodysesthesia, rash , alopecia , erythema , dryness, pruritus, hyperpigmentation , rash, peeling , dermatitis , abnormal pigmentation, and…
- Trial name
- B-DUOL (NCT02036957)
- Testing
- BALM ARM
- Where
- Spain
- Volunteers
- 86 people
- Sponsor
- Basque Health Service